Treatment of metastatic refractory colorectal cancer following regorafenib failure

Takeuchi,Nobumichi; Koike,Kumiko; Yoshida,Sonomi; Kudo,Akiko; Sekiguchi,Nodoka; Nakayama,Ataru; Kubota,Kouji; Rokuhara,Takashi; Kitahara,Masayuki

doi:10.3892/mco.2017.1307

August-2017 Volume 7 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2017 Volume 7 Issue 2

Full Size Image

Article

Treatment of metastatic refractory colorectal cancer following regorafenib failure

Authors:
- Nobumichi Takeuchi
- Kumiko Koike
- Sonomi Yoshida
- Akiko Kudo
- Nodoka Sekiguchi
- Ataru Nakayama
- Kouji Kubota
- Takashi Rokuhara
- Masayuki Kitahara
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Ina Central Hospital, Ina, Nagano 396‑8555, Japan, Department of Comprehensive Cancer Therapy, School of Medicine, Shinsyu University, Matsumoto, Nagano 396‑8621, Japan, Department of Surgery, Ina Central Hospital, Ina, Nagano 396‑8555, Japan, Department of Pharmacology, Ina Central Hospital, Ina, Nagano 396‑8555, Japan
Pages: 308-312
|
Published online on: June 29, 2017

https://doi.org/10.3892/mco.2017.1307
Expand metrics +

Abstract

At present, there is no set strategy for the treatment of patients with colorectal cancer subsequent to the failure of standard treatment, other than the use of regorafenib (RGR) and TAS‑102. The best order in which to use these drugs, and their safety and efficacy in combination with other drugs, are currently under investigation. It has been reported that RGR has a resensitizing effect on tumors that have previously failed to respond to anticancer drugs; this makes it a promising salvage therapy for colorectal cancer. The present report describes the results of a retrospective study on 17 patients with metastatic colorectal cancer who received RGR treatment following the failure of standard therapy. Following RGR failure, 71% of the patients were fit for further anticancer treatment, and these patients survived longer than those who did not receive further treatment. Furthermore, this intervention did not shorten the period of best supportive care. As a considerable number patients were fit for further anticancer therapy after RGR treatment, which resulted in prolonged survival without shortening the period of best supportive care, it may be beneficial for future research to focus on finding the optimal time at which to switch from RGR to further anticancer therapy.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Treatment of metastatic refractory colorectal cancer following regorafenib failure

This article is mentioned in:

Abstract

Related Articles